Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Log out
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Metabolism

Postprandial Administration of Intranasal Insulin Intensifies Satiety and Reduces Intake of Palatable Snacks in Women

  1. Manfred Hallschmid1⇓,
  2. Suzanne Higgs2,
  3. Matthias Thienel1,
  4. Volker Ott1 and
  5. Hendrik Lehnert3
  1. 1Department of Neuroendocrinology, University of Lübeck, Lübeck, Germany
  2. 2School of Psychology, University of Birmingham, Birmingham, U.K.
  3. 3Department of Internal Medicine I, University of Lübeck, Lübeck, Germany
  1. Corresponding author: Manfred Hallschmid, hallschmid{at}kfg.uni-luebeck.de.
Diabetes 2012 Apr; 61(4): 782-789. https://doi.org/10.2337/db11-1390
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

The role of brain insulin signaling in the control of food intake in humans has not been thoroughly defined. We hypothesized that the hormone contributes to the postprandial regulation of appetite for palatable food, and assessed the effects on appetite and snack intake of postprandial versus fasted intranasal insulin administration to the brain in healthy women. Two groups of subjects were intranasally administered 160 IU insulin or vehicle after lunch. Two hours later, consumption of cookies of varying palatability was measured under the pretext of a taste test. In a control study, the effects of intranasal insulin administered to fasted female subjects were assessed. Compared with placebo, insulin administration in the postprandial but not in the fasted state decreased appetite as well as intake and rated palatability of chocolate chip cookies (the most palatable snack offered). In both experiments, intranasal insulin induced a slight decrease in plasma glucose but did not affect serum insulin concentrations. Data indicate that brain insulin acts as a relevant satiety signal during the postprandial period, in particular reducing the intake of highly palatable food, and impacts peripheral glucose homeostasis. Postprandial intranasal insulin administration might be useful in curtailing overconsumption of snacks with accentuated rewarding value.

Observations in animals that the central nervous application of insulin decreases food intake (1,2) have led to the current concept that insulin, which reaches the brain via a receptor-mediated saturable transport (3), acts as a negative feedback signal in the homeostatic regulation of body weight (4). In humans, intranasal administration of the hormone enables the assessment of brain insulin effects in the absence of relevant systemic absorption (5). Thus, intranasal insulin has been shown to reduce food intake after acute administration (6) and to decrease body fat after long-term treatment (7). These effects were observed in men but not in women, which is in accordance with animal studies in which male but not female rats decreased food intake and lost body weight during 24 h of intracerebroventricular insulin administration (2,8). This pattern suggests that the contribution of brain insulin to the control of energy intake displays a certain degree of sex specificity. However, neuroimaging experiments have yielded evidence for food-related central nervous effects of insulin in women (9–11). These conflicting results highlight the fact that the preconditions and mechanisms of the anorexigenic impact of brain insulin signaling in humans are poorly understood. Notably, the acute reduction in food intake elicited by intranasal insulin administration (6) but also intravenous infusion of the insulin analog detemir (12) in the fasted state was not preceded by changes in self-rated hunger, implying that central nervous insulin exerts its anorexigenic effects via signals that contribute to meal termination and satiety rather than by reducing hunger motivation in fasted subjects (13).

Recent evidence indicates that in addition to acting on homeostatic, i.e., primarily hypothalamic, networks of food intake control, insulin modulates extrahypothalamic neural pathways processing the rewarding aspects of energy intake (14). Also, recalling previous lunch decreases afternoon snack intake in women (15,16), suggesting that the reward component of insulin’s satiating impact might be further promoted by the memory-improving effect of the hormone (17). Against this background, we hypothesized that intranasal insulin administration in the postprandial but not in the fasted state decreases subsequent intake of palatable snacks in women, who in this context also served as a model of moderate central nervous insulin sensitivity. We also assumed that the satiating impact of the hormone might be associated with improved recall of previous lunch intake.

RESEARCH DESIGN AND METHODS

Subjects were young healthy women who were taking oral (estrogen dominant, single-phase) contraceptives but were otherwise free of medication and were nonsmokers. All relevant illness was excluded by clinical examination. Habitual eating behavior was assessed via a lifestyle questionnaire on dietary restraint and tendency toward disinhibition (15). In brief, dietary restraint, i.e., the conscious effort to restrict calorie intake to control body weight was assessed using the restraint scale of the Dutch Eating Behavior Questionnaire (18). Only subjects with a score of 2.3, i.e., the median score for European populations (19), or less were included. Tendency toward disinhibition was assessed with the disinhibition scale of the Three Factor Eating Questionnaire (20), with an inclusion score of 8 or less. Subjects were kept unaware of hypothesized treatment effects on food intake and were informed that the experiments concerned the effect of insulin on taste preferences. Participants gave written informed consent to the studies, which conformed to the Declaration of Helsinki and were approved by the local ethics committee. All experiments were performed in a double-blind fashion.

Design and procedure of experiments I and II.

For experiment I (Fig. 1A), 30 women were randomly assigned to two groups, insulin and placebo, that were closely comparable regarding age (22.27 ± 0.73 vs. 23.13 ± 0.99 years, P = 0.49), BMI (21.47 ± 0.37 vs. 21.13 ± 0.36 kg/m2, P = 0.51), as well as prescreening scores of dietary restraint (1.71 ± 0.09 vs. 1.68 ± 0.08, P = 0.59) and disinhibition tendency (4.47 ± 0.41 vs. 4.87 ± 0.49, P = 0.54). Each woman participated in one individual experimental session (one participant per session) scheduled not to take place during her menstruation phase. Participants were instructed to abstain from caffeinated and alcoholic beverages after 2000 h on the day preceding the experiment, to have regular breakfast before 0800 h of the experimental day and to stay fasted afterward. After arrival at the laboratory around 1100 h, a venous cannula was inserted into the subject’s nondominant arm, which was positioned in a heated box (55°C) to enable drawing of arterialized venous blood.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Experimental procedures. A: In experiment I, healthy young women consumed lunch at 1230 h and were intranasally administered insulin (160 IU; n = 15) or placebo (n = 15) at 1300 h. At 1500 h, free lunch recall took place, and 5 min later, snack intake was assessed with the participants assuming a taste rating task. Throughout the session, vigilance, mood, appetite, and thirst were assessed, and blood samples were taken (syringe symbols). B: In experiment II, insulin and placebo administration, respectively, took place at 1000 h and snack intake was assessed at 1215 h immediately after lunch serving as a preload (n = 13). The interval between insulin administration and snack intake assessment was kept constant between both experiments.

Experimental sessions started around 1145 h with baseline blood sampling and assessments of vigilance, mood, appetite, and thirst. From 1230–1245 h lunch was served, followed at 1300 h by the intranasal administration of 16 0.1-mL puffs (8 per nostril) of insulin or placebo at 60-s intervals, amounting to a total dose of 1.6 mL insulin (160 IU; Insulin Actrapid; Novo Nordisk, Mainz, Germany) or vehicle (6,21). At 1500 h, after a further 2 h of repeated blood sampling and vigilance, mood, appetite, and thirst assessments, participants of both groups were asked to write down as precisely and completely as possible what they had had for lunch. They were left alone for 5 min to do this. Free lunch recall protocols were quantified offline by a person blinded to the respective experimental group. Immediately after lunch recall, snack intake was assessed under the pretext of a cookie taste test. The experiment ended with another assessment of vigilance, mood, appetite, and thirst.

Experiment II (Fig. 1B) was carried out to assess whether the insulin effects observed in experiment I are specific to the postprandial state. A group of 13 women (age, 22.77 ± 0.61 years; BMI, 22.89 ± 0.52 kg/m2; restraint, 2.20 ± 0.07; disinhibition, 3.92 ± 0.49) participated in two conditions (insulin and placebo) spaced apart 28 days, ensuring participation on identical days in the menstrual cycle (with the exception of the menstruation phase). The order of conditions was balanced across subjects. After an overnight fast, subjects arrived at the laboratory around 0815 h and, after preparation of blood sampling and baseline measurements, were intranasally administered 160 IU insulin and placebo, respectively, at 1000 h, i.e., in the fasted state. Two hours later, snack intake was assessed following lunch, which in this instance served as a caloric preload. Substance administration, lunch procedure, snack intake assessment, repeated blood sampling, and behavioral assessments of vigilance, mood, appetite, and thirst were identical to experiment I. In both experiments, interviews at the end of the sessions confirmed that none of the participants had been aware of the purpose of the study.

Lunch and assessment of snack intake.

For lunch, the participant was presented with six hot, freshly baked mini pizzas (∼400 kcal; flavors “Hawaiian,” bacon, cheese, and salami) each cut into quarters to conceal portion size, yielding 24 pieces of pizza. A bottle of still mineral water was also provided. The participant was asked to rate the palatability of the pizzas on a visual analog scale (VAS) anchored at 0 (not palatable) and 100 (highly palatable). Each participant was asked to consume the whole meal, being told that this was “to make the ratings fair.”

The snack test at the end of experiments was based on the procedure used by Rogers and Hill (22) and by Higgs and colleagues (15,16). Three plates of cookies were placed on the table, each containing a different variety and labeled Cookie A, B, and C, respectively. The three types were premium spritz cookies, crunchy coconut cookies, and chocolate chip cookies, respectively (Coppenrath, Geeste, Germany; Table 1). Of each variety, 15 cookies broken into bite-sized pieces were provided, allowing for a considerable amount to be eaten without the plates appearing empty to ensure that participants would not restrict cookie intake based on whether the experimenter could see how much had been consumed. In addition, a glass of still mineral water was provided. The participant was instructed to taste and rate each type of cookie on a VAS assessing palatability (0–100). The importance of giving accurate ratings was emphasized and subjects were informed that during and after completion of the rating task they could eat as many cookies as they liked because any remaining cookies would be discarded, and then they were left alone for 10 min. Cookie intake was measured by weighing the cookies before and after the cookie taste test.

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Snack test cookies

Measurements of vigilance, mood, appetite, and thirst.

During both experiments, subjects repeatedly performed a simple 5-min PC-based vigilance task. In this task, a digital millisecond counter appeared at random intervals in the middle of the screen, starting at 0 ms to count upwards, and subjects were required to press a key as fast as possible, receiving immediate feedback in the form of the reaction time. For each 5-min task, mean reaction time was registered. Self-reported mood was assessed with 5-point scales covering the categories good/bad mood, alertness/sleepiness, and calmness/agitation (MDBF; 23), and with a checklist containing 123 adjectives assessing mood on 14 dimensions (EWL-K; 24). Appetite and thirst were rated on VASs anchored at 0 and 100. Heart rate and blood pressure were monitored throughout the experimental sessions.

Plasma glucose and hormone concentrations.

In both experiments, blood glucose concentrations were monitored online using the HemoCue B-Glucose Analyzer (Ängelholm, Sweden). Blood samples for the subsequent assessment of plasma glucose, serum insulin, and C-peptide (in both experiments) as well as of plasma ACTH and ghrelin and serum cortisol and leptin (experiment I) were centrifuged immediately, and serum and plasma were stored at –20°C. Routine assays were used to determine concentrations of plasma glucose (measured in fluoride plasma according to the hexokinase method [Aeroset; Abbott Diagnostics, North Chicago, IL]); insulin, C-peptide, ACTH, cortisol (all Immulite; DPC, Los Angeles, CA); and total ghrelin and leptin (radioimmunoassay; Millipore, Billerica, MA).

Statistical analysis.

Comparisons between the effects of insulin and placebo were based on ANOVA with the between-subjects factor “group” (experiment I) and the within-subjects factor “treatment” (experiment II), respectively, and the factors time or cookie type as appropriate. Significant interaction effects were specified by pairwise t tests. All data are presented as means ± SE. A P value < 0.05 was considered significant.

RESULTS

Experiment I: postprandial intranasal insulin administration reduces appetite and intake of palatable snacks.

In experiment I, lunch intake induced a sharp decline in rated appetite in both groups (P < 0.001 for time; Fig. 2A). Postprandial administration of insulin abrogated the subsequent rise in appetite ratings that slowly emerged in the control group before the snack test (P = 0.04 for group × time). Total cookie intake at 1505 h did not differ between groups (insulin, 244.75 ± 22.94 kcal; placebo, 257.73 ± 17.09 kcal; P = 0.65). However, intake of chocolate chip cookies was significantly reduced in the insulin compared with the placebo group (76.11 ± 12.01 vs. 112.74 ± 13.15 kcal, P = 0.049; P = 0.049 for group × cookie type), whereas consumption of spritz cookies and coconut cookies was not affected (both P > 0.29; Fig. 2B). Accordingly, although the placebo group consumed more chocolate chip than other cookies (P = 0.016), this relation was absent in the insulin group (P = 0.55; P = 0.021 for the respective group effect). A corresponding pattern was revealed for snack palatability ratings, which globally did not differ between groups (P = 0.39; Fig. 2C) but with regard to chocolate chip cookies were distinctly reduced after insulin compared with placebo administration (56.48 ± 5.70 vs. 72.88 ± 3.92, P = 0.025; P = 0.049 for group × cookie type). Thus, chocolate chip cookies were rated significantly more palatable than the remaining cookie types in the placebo (P = 0.015) but not in the insulin group (P = 0.22; P = 0.014 for group effect).

FIG. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 2.

Appetite and snack intake in experiments I and II. A: Appetite rated on visual analog scales anchored at 0 and 100 throughout experiment I in a group of subjects who were intranasally administered insulin (160 IU; black dots and solid lines; n = 15) at 1300 h (nose symbol) and a placebo control group (white dots and dashed lines; n = 15). Lunch was consumed at 1230 h and snacks were offered at 1505 h. B: Snack intake (kcal) assessed at 1505 h under the pretext of a taste rating session in the placebo group (white bars) and the insulin group (black bars) of experiment I. Three different types of cookies were offered. C: Snack palatability rated on visual analog scales anchored at 0 (not palatable) and 100 (highly palatable) during the snack test at 1505 h (experiment I). *P < 0.05 for comparisons between groups (t tests). D–F: Respective results obtained in the 13 subjects of experiment II who were intranasally administered insulin (160 IU; black dots, solid lines) (D; nose symbol) and placebo (white dots, dashed lines), respectively, at 1000 h. The snack test took place at 1215 h. Values are means ± SE.

Palatability ratings of the mini pizzas offered for lunch were comparable between the placebo (74.27 ± 5.75) and the insulin groups (75.67 ± 3.48, P = 0.84). Protocols of free lunch recall yielded full data sets for the categories “number of consumed mini pizzas” and “number of pizza types.” Both scores did not differ between groups (placebo vs. insulin, 5.92 ± 0.33 vs. 5.33 ± 0.19, P = 0.12; and 2.85 ± 0.22 vs. 3.00 ± 0.20, P = 0.61, respectively). Throughout the experimental sessions, thirst ratings (P = 0.50) and mood according to MDBF (all P > 0.33) and EWL-K scales (P > 0.13) were comparable between groups, as were reaction times in the vigilance task (P > 0.68), heart rate (P > 0.28), and blood pressure (P > 0.53).

Experiment II: intranasal insulin administration in the fasted state does not affect appetite and snack intake.

In experiment II, appetite ratings increased until they dropped after pizza and snack intake, with no differences between conditions (P = 0.59 for treatment × time; Fig. 2D). Snack consumption at 1215 h did not differ regarding total intake (insulin, 355.61 ± 59.12 kcal; placebo, 314.24 ± 30.48 kcal; P = 0.33) and intake according to cookie type (all P > 0.14; Fig. 2E). Intranasal insulin did not affect palatability ratings globally (P = 0.12) nor according to cookie type (P = 0.74; Fig. 2F). Across conditions, intake (P = 0.003) and palatability ratings (P = 0.039) of chocolate chip cookies exceeded those of the remaining types. Palatability ratings of the pizza lunch were comparable between the placebo (75.62 ± 6.59) and the insulin conditions (79.69 ± 2.82, P = 0.59). Insulin treatment likewise did not alter thirst ratings (P = 0.78), mood according to MDBF (all P > 0.28) and EWL-K scales (P > 0.09), vigilance (P > 0.26), heart rate (P > 0.29), or blood pressure (P > 0.73).

Exploratory comparisons between both experiments revealed that neither snack intake (P = 0.068) nor rated snack palatability (P = 0.59) generally differed between the two groups of experiment I and the subjects of experiment II (collapsed conditions). In both experiments, subjects could not correctly indicate at the end of the session whether they had received insulin or placebo (experiment I, P = 0.12; experiment II, P = 0.69; χ2 tests).

Plasma glucose and endocrine parameters.

In both experiments, blood parameters did not differ during baseline (all P > 0.07). In experiment I, concentrations of plasma glucose (P = 0.016 for group × time) and serum C-peptide (P = 0.021) displayed slight reductions in the insulin compared with the placebo group that emerged after intranasal insulin administration but were no longer detectable before the snack test (Fig. 3A and B). Serum insulin (P = 0.12) and leptin (P = 0.11) were not affected by insulin administration; Fig. 3C and D). Plasma ghrelin concentrations showed the expected postprandial decrease with no significant differences between groups (P = 0.077; Fig. 3E). Likewise, there were no treatment effects on plasma ACTH (P = 0.42) and serum cortisol (P = 0.70). In line with experiment I, in experiment II plasma glucose concentrations were slightly reduced following intranasal insulin (P = 0.031 for treatment × time), averaging 4.36 ± 0.09 mmol/L in the insulin and 4.63 ± 0.09 mmol/L in the placebo condition between 1045 h and 1145 h (P = 0.002). C-peptide concentrations also decreased following intranasal insulin (P = 0.001 for treatment × time; 0.30 ± 0.03 vs. 0.42 ± 0.03 nmol/L, P = 0.001), whereas serum insulin levels did not differ between conditions (P = 0.57).

FIG. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 3.

Plasma glucose and hormonal parameters in experiment I. Concentrations of plasma glucose (A), serum C-peptide (B), serum insulin (C), serum leptin (D), and plasma ghrelin (E) measured throughout experiment I in a group of subjects who were intranasally administered insulin (160 IU; black dots and solid lines; n = 15) at 1300 h (nose symbol) and a placebo control group (white dots and dashed lines; n = 15). Lunch was consumed at 1230 h, and snacks were offered at 1505 h. Values are means ± SE. *P < 0.05 for comparisons between groups (t tests).

DISCUSSION

Intranasal insulin administration to the brain has anorexigenic and catabolic properties in male subjects (6,7), but the precise role of the hormone in the acute regulation of food intake in humans has not yet been characterized. By demonstrating that intranasal insulin administration in the postprandial but not in the fasted state reduces appetite and snack intake in women, we provide evidence for the notion that insulin acts as a satiety signal in humans. As the insulin-induced reduction in snack intake was only found for hedonically salient but not for less palatable snacks, our findings moreover suggest that postprandial insulin in particular modulates the reward-related, nonhomeostatic control of food intake.

In line with previous results (6,21,25), in both experiments plasma glucose concentrations slightly decreased immediately after intranasal insulin administration but clearly remained within the euglycemic range. It might be speculated that intranasally administered insulin accessing relevant hypothalamic structures acted on the glucoregulatory brain-liver axis. By opening ATP-sensitive K+ channels of glucose-responsive hypothalamic neurons (26,27), intracerebroventricularly administered insulin can decrease hepatic glucose production by more than 40% (28) and plasma glucose concentrations by more than 1 mmol/L (27) in rats. These findings are in line with related results in canines (29,30), but discordant canine data (31,32) have sparked controversy about the relevance of brain insulin for peripheral glucose homeostasis in different species. Remarkably, activation of ATP-sensitive K+ channels by oral diazoxide has most recently been reported to suppress endogenous glucose production in healthy humans (33). Although against this background a centrally mediated effect of intranasal insulin on plasma glucose appears likely (25), more refined measures of peripheral glucose metabolism will be needed to substantiate this conclusion. Also, the decrease in C-peptide concentrations might reflect attenuated secretion of endogenous insulin due to a small ratio of intranasal insulin entering the blood stream via the nasal mucosa (10).

In experiment I, intranasal insulin administered immediately after lunch markedly enhanced the satiating effect of food intake, keeping appetite ratings at postlunch levels, whereas they slowly rose again in the control group, and reducing snack intake from chocolate chip cookies. In contrast, neither appetite nor snacking were affected by insulin administered in the fasted state in experiment II, a finding that replicates our previous results in women (6,21). Importantly, rated lunch and snack palatability as well as overall snack intake did not differ between both experiments, identifying the postprandial timing as the critical determinant of insulin’s impact on chocolate chip cookie intake. Thus, although in accordance with experiments in rodents (2,8), women per se are less sensitive to the anorexigenic impact of brain insulin than men who decrease food intake in response to intranasal insulin administration in the fasted state (6), brain insulin feedback can be assumed to exert a satiating effect not only in males but also in females. Although intranasal insulin administration may have enhanced and prolonged the postprandial brain insulin signal (5,34), the sharp postlunch decline in appetite in conjunction with meal-related insulin secretion observed in the placebo group of experiment I is in accordance with the notion of postprandial insulin acting as a physiological satiating factor. Support for this assumption comes from studies showing that the postprandial surge in circulating insulin is associated with increased satiety and reduced energy intake (35) as well as a reduction in regional cerebral blood flow in the orbitofrontal cortex (36) whose activity predicts feeding behavior, particularly in the fed state (37). Considering that remembering a preceding meal has been previously shown to decrease snack consumption (15,16) and that intranasal insulin improves declarative, hippocampus-dependent memory functions (6,17), experiment I included a free recall of lunch memory which, however, did not yield any signs of insulin-improved meal memory. Although more subtle insulin-induced cognitive changes might have eluded our attention, this finding does not support the assumption that the satiating impact of insulin depends on an improvement of food-specific memory functions.

Of note, the insulin-induced reduction in rated palatability and intake of snacks was restricted to chocolate chip cookies, which according to palatability ratings had the strongest rewarding quality but regarding nutritional values were comparable to the other snacks. This pattern suggests that in addition to promoting satiety, e.g., by enhancing the sensitivity to signals such as cholecystokinin (38), insulin administration also affected nonhomeostatic pathways that mediate reward-related “hedonic” aspects of food intake. Accordingly, in neuroimaging studies in fasted men and women who were presented pictures of food stimuli, intranasal insulin reduced activity of the fusiform gyrus (10), an area that also displays reduced activity during satiation (39) but increased activation when subjects experience food liking or food craving (40). Insulin did not affect general mood in our participants, indicating that the attenuating impact on hedonic processing is food-specific. Although the suppressive effect of central nervous insulin on food intake in general has been repeatedly demonstrated in animals (e.g., 1,2,8), recent experiments have provided a neurophysiological framework for a role of the hormone in hedonic food processing (rev. in 14). Thus, insulin receptors are expressed in dopaminergic neurons of the ventral tegmental area and substantia nigra (41), and brain administration of insulin decreases the rewarding quality of food (42–44) presumably by suppressing mesolimbic dopaminergic signaling (45). Respective experimental paradigms simulate a dessert or between-meal snack experience (46) similar to the present experiments, and it will be important to examine which types of palatable food are subject to insulin’s “anhedonic” impact in humans.

In summary, we demonstrate that postprandially administered intranasal insulin enhances the satiating effect of meals and reduces palatable snack intake, suggesting that insulin acts as a relevant signal in the short-term regulation of satiety in humans. Our results were obtained in women, who in comparison with men display generally reduced sensitivity to insulin’s anorexigenic brain effect (6,7,21). Thus, postprandial insulin administration might be speculated to also decrease intake of palatable snacks in obesity, which is characterized by central nervous insulin resistance (9,11,47) and a blunted association between postprandial insulin secretion and satiety (35). Considering that the rewarding effect of palatable food overriding the homeostatic control of energy intake may promote obesity (48), insulin’s potential to curb the appetite for hedonically salient, calorie-rich food deserves particular attention.

ACKNOWLEDGMENTS

This study was supported by Deutsche Forschungsgemeinschaft (KFO 126/B5). The funding source had no input in the design and conduct of this study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the article.

No potential conflicts of interest relevant to this article were reported.

M.H., S.H., and H.L. designed the study. M.H., S.H., M.T., and V.O. analyzed the data. M.H. enrolled students and collected data or did experiments for the study. M.H., S.H., M.T., V.O., and H.L. discussed the results and contributed to writing the manuscript. M.H. and S.H. wrote the manuscript. All authors take full responsibility for the contents of the article. M.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Monique Friedrich, Meike Gaul, Anne Martin (all from the Department of Neuroendocrinology, University of Lübeck, Lübeck, Germany), and Kirstin Nordhausen (Internal Medicine I, University of Lübeck) for their expert technical assistance and Martina Grohs, Heidi Ruf, Ingrid von Lützau (all from the Department of Neuroendocrinology, University of Lübeck), and Jutta Schwanbom (Internal Medicine I, University of Lübeck) for their invaluable laboratory work.

Footnotes

  • See accompanying commentary, p. 773.

  • Received October 2, 2011.
  • Accepted December 18, 2011.
  • © 2012 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Woods SC,
    2. Lotter EC,
    3. McKay LD,
    4. Porte D Jr.
    . Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979;282:503–505pmid:116135
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Clegg DJ,
    2. Riedy CA,
    3. Smith KA,
    4. Benoit SC,
    5. Woods SC
    . Differential sensitivity to central leptin and insulin in male and female rats. Diabetes 2003;52:682–687pmid:12606509
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Woods SC,
    2. Seeley RJ,
    3. Baskin DG,
    4. Schwartz MW
    . Insulin and the blood-brain barrier. Curr Pharm Des 2003;9:795–800pmid:12678878
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Belgardt BF,
    2. Brüning JC
    . CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci 2010;1212:97–113pmid:21070248
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Born J,
    2. Lange T,
    3. Kern W,
    4. McGregor GP,
    5. Bickel U,
    6. Fehm HL
    . Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 2002;5:514–516pmid:11992114
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Benedict C,
    2. Kern W,
    3. Schultes B,
    4. Born J,
    5. Hallschmid M
    . Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 2008;93:1339–1344pmid:18230654
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Hallschmid M,
    2. Benedict C,
    3. Schultes B,
    4. Fehm HL,
    5. Born J,
    6. Kern W
    . Intranasal insulin reduces body fat in men but not in women. Diabetes 2004;53:3024–3029pmid:15504987
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Clegg DJ,
    2. Brown LM,
    3. Woods SC,
    4. Benoit SC
    . Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes 2006;55:978–987pmid:16567519
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Tschritter O,
    2. Preissl H,
    3. Hennige AM,
    4. et al
    . The cerebrocortical response to hyperinsulinemia is reduced in overweight humans: a magnetoencephalographic study. Proc Natl Acad Sci USA 2006;103:12103–12108pmid:16877540
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Guthoff M,
    2. Grichisch Y,
    3. Canova C,
    4. et al
    . Insulin modulates food-related activity in the central nervous system. J Clin Endocrinol Metab 2010;95:748–755pmid:19996309
    OpenUrlCrossRefPubMed
  11. ↵
    1. Guthoff M,
    2. Stingl KT,
    3. Tschritter O,
    4. et al
    . The insulin-mediated modulation of visually evoked magnetic fields is reduced in obese subjects. PLoS ONE 2011;6:e19482pmid:21589921
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hallschmid M,
    2. Jauch-Chara K,
    3. Korn O,
    4. et al
    . Euglycemic infusion of insulin detemir compared with human insulin appears to increase direct current brain potential response and reduces food intake while inducing similar systemic effects. Diabetes 2010;59:1101–1107pmid:20068139
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Woods SC,
    2. Seeley RJ,
    3. Porte D Jr.,
    4. Schwartz MW
    . Signals that regulate food intake and energy homeostasis. Science 1998;280:1378–1383pmid:9603721
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Könner AC,
    2. Klöckener T,
    3. Brüning JC
    . Control of energy homeostasis by insulin and leptin: targeting the arcuate nucleus and beyond. Physiol Behav 2009;97:632–638pmid:19351541
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Higgs S
    . Memory for recent eating and its influence on subsequent food intake. Appetite 2002;39:159–166pmid:12354684
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Higgs S,
    2. Williamson AC,
    3. Attwood AS
    . Recall of recent lunch and its effect on subsequent snack intake. Physiol Behav 2008;94:454–462pmid:18420236
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Benedict C,
    2. Hallschmid M,
    3. Hatke A,
    4. et al
    . Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004;29:1326–1334pmid:15288712
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. van Strien T,
    2. Frijters JER,
    3. van Staveren WA,
    4. Defares PB,
    5. Deurenberg P
    . The predictive validity of the Dutch Restrained Eating Scale. Int J Eat Disord 1986;5:747–755
    OpenUrlCrossRefWeb of Science
  19. ↵
    1. Allison DB
    1. Gorman BS,
    2. Allison DB
    . Measures of restrained eating. In Handbook of Assessment Methods for Eating Behaviours and Weight-Related Problems. Allison DB, Ed. Thousand Oak, CA, Sage, 1995, p. 149–184
  20. ↵
    1. Stunkard AJ,
    2. Messick S
    . The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985;29:71–83pmid:3981480
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Krug R,
    2. Benedict C,
    3. Born J,
    4. Hallschmid M
    . Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 2010;95:E468–E472pmid:20719831
    OpenUrlCrossRefPubMed
  22. ↵
    1. Rogers PJ,
    2. Hill AJ
    . Breakdown of dietary restraint following mere exposure to food stimuli: interrelationships between restraint, hunger, salivation, and food intake. Addict Behav 1989;14:387–397pmid:2782122
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Steyer R,
    2. Schwenkmezger P,
    3. Notz P,
    4. Eid M
    . Der mehrdimensionale Befindlichkeitsfragebogen (MDBF). Handanweisung. Göttingen, Hogrefe, 1997
  24. ↵
    1. Janke W,
    2. Debus G
    . Die Eigenschaftswörterliste (EWL). Göttingen, Hogrefe, 1978
  25. ↵
    1. Benedict C,
    2. Brede S,
    3. Schiöth HB,
    4. et al
    . Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men. Diabetes 2011;60:114–118pmid:20876713
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Spanswick D,
    2. Smith MA,
    3. Mirshamsi S,
    4. Routh VH,
    5. Ashford ML
    . Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats. Nat Neurosci 2000;3:757–758pmid:10903566
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Pocai A,
    2. Lam TK,
    3. Gutierrez-Juarez R,
    4. et al
    . Hypothalamic K(ATP) channels control hepatic glucose production. Nature 2005;434:1026–1031pmid:15846348
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Obici S,
    2. Zhang BB,
    3. Karkanias G,
    4. Rossetti L
    . Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002;8:1376–1382pmid:12426561
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Agarwala GC,
    2. Mittal RK,
    3. Bapat SK,
    4. Bhardwaj UR
    . Effect of centrally administered insulin on blood glucose levels in dogs. Indian J Physiol Pharmacol 1977;21:11–18pmid:873587
    OpenUrlPubMed
  30. ↵
    1. Chowers I,
    2. Lavy S,
    3. Halpern L
    . Effect of insulin administered intracisternally on the glucose level of the blood and the cerebrospinal fluid in vagotomized dogs. Exp Neurol 1966;14:383–389pmid:4952826
    OpenUrlCrossRefPubMed
  31. ↵
    1. Edgerton DS,
    2. Lautz M,
    3. Scott M,
    4. et al
    . Insulin’s direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006;116:521–527pmid:16453026
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Ramnanan CJ,
    2. Saraswathi V,
    3. Smith MS,
    4. et al
    . Brain insulin action augments hepatic glycogen synthesis without suppressing glucose production or gluconeogenesis in dogs. J Clin Invest 2011;121:3713–3723pmid:21865644
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Kishore P,
    2. Boucai L,
    3. Zhang K,
    4. et al
    . Activation of KATP channels suppresses glucose production in humans. J Clin Invest 2011;121:4916–4920pmid:22056385
    OpenUrlCrossRefPubMed
  34. ↵
    1. Hallschmid M,
    2. Schultes B,
    3. Marshall L,
    4. et al
    . Transcortical direct current potential shift reflects immediate signaling of systemic insulin to the human brain. Diabetes 2004;53:2202–2208pmid:15331528
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Flint A,
    2. Gregersen NT,
    3. Gluud LL,
    4. et al
    . Associations between postprandial insulin and blood glucose responses, appetite sensations and energy intake in normal weight and overweight individuals: a meta-analysis of test meal studies. Br J Nutr 2007;98:17–25pmid:17524176
    OpenUrlCrossRefPubMed
  36. ↵
    1. Tataranni PA,
    2. Gautier JF,
    3. Chen K,
    4. et al
    . Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography. Proc Natl Acad Sci USA 1999;96:4569–4574pmid:10200303
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Batterham RL,
    2. ffytche DH,
    3. Rosenthal JM,
    4. et al
    . PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 2007;450:106–109pmid:17934448
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Riedy CA,
    2. Chavez M,
    3. Figlewicz DP,
    4. Woods SC
    . Central insulin enhances sensitivity to cholecystokinintranasal Physiol Behav 1995;58:755–760pmid:8559787
    OpenUrlCrossRefPubMed
  39. ↵
    1. LaBar KS,
    2. Gitelman DR,
    3. Parrish TB,
    4. Kim YH,
    5. Nobre AC,
    6. Mesulam MM
    . Hunger selectively modulates corticolimbic activation to food stimuli in humans. Behav Neurosci 2001;115:493–500pmid:11345973
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Pelchat ML,
    2. Johnson A,
    3. Chan R,
    4. Valdez J,
    5. Ragland JD
    . Images of desire: food-craving activation during fMRI. Neuroimage 2004;23:1486–1493pmid:15589112
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Figlewicz DP,
    2. Evans SB,
    3. Murphy J,
    4. Hoen M,
    5. Baskin DG
    . Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 2003;964:107–115pmid:12573518
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Sipols AJ,
    2. Stuber GD,
    3. Klein SN,
    4. Higgins MS,
    5. Figlewicz DP
    . Insulin and raclopride combine to decrease short-term intake of sucrose solutions. Peptides 2000;21:1361–1367pmid:11072123
    OpenUrlCrossRefPubMedWeb of Science
    1. Figlewicz DP,
    2. Bennett J,
    3. Evans SB,
    4. Kaiyala K,
    5. Sipols AJ,
    6. Benoit SC
    . Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats. Behav Neurosci 2004;118:479–487pmid:15174925
    OpenUrlCrossRefPubMedWeb of Science
  43. ↵
    1. Figlewicz DP,
    2. Benoit SC
    . Insulin, leptin, and food reward: update 2008. Am J Physiol Regul Integr Comp Physiol 2009;296:R9–R19pmid:18945945
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Figlewicz DP,
    2. Szot P,
    3. Chavez M,
    4. Woods SC,
    5. Veith RC
    . Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 1994;644:331–334pmid:8050044
    OpenUrlCrossRefPubMedWeb of Science
  45. ↵
    1. Figlewicz DP,
    2. Bennett JL,
    3. Aliakbari S,
    4. Zavosh A,
    5. Sipols AJ
    . Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats. Am J Physiol Regul Integr Comp Physiol 2008;295:R388–R394pmid:18525010
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Hallschmid M,
    2. Benedict C,
    3. Schultes B,
    4. Born J,
    5. Kern W
    . Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) 2008;32:275–282pmid:17848936
    OpenUrlCrossRefPubMed
  47. ↵
    1. Kenny PJ
    . Reward mechanisms in obesity: new insights and future directions. Neuron 2011;69:664–679pmid:21338878
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes: 61 (4)

In this Issue

April 2012, 61(4)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Postprandial Administration of Intranasal Insulin Intensifies Satiety and Reduces Intake of Palatable Snacks in Women
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Postprandial Administration of Intranasal Insulin Intensifies Satiety and Reduces Intake of Palatable Snacks in Women
Manfred Hallschmid, Suzanne Higgs, Matthias Thienel, Volker Ott, Hendrik Lehnert
Diabetes Apr 2012, 61 (4) 782-789; DOI: 10.2337/db11-1390

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Postprandial Administration of Intranasal Insulin Intensifies Satiety and Reduces Intake of Palatable Snacks in Women
Manfred Hallschmid, Suzanne Higgs, Matthias Thienel, Volker Ott, Hendrik Lehnert
Diabetes Apr 2012, 61 (4) 782-789; DOI: 10.2337/db11-1390
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Ncor2/PPARα-Dependent Upregulation of MCUb in the Type 2 Diabetic Heart Impacts Cardiac Metabolic Flexibility and Function
  • Role of the Neutral Amino Acid Transporter SLC7A10 in Adipocyte Lipid Storage, Obesity, and Insulin Resistance
  • Heme Oxygenase-1 Regulates Ferrous Iron and Foxo1 in Control of Hepatic Gluconeogenesis
Show more Metabolism

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.